Next Article in Journal
Innovative Spine Implants for Improved Augmentation and Stability in Neoplastic Vertebral Compression Fracture
Previous Article in Journal
A Meta-Analysis of the Utility of Preoperative Intravenous Paracetamol for Post-Caesarean Analgesia
Article Menu

Export Article

Open AccessReview

Investigation of ATG16L1 rs2241880 Polymorphism with Cancer Risk: A Meta-Analysis

1
Department of Clinical Biochemistry, Iranshahr University of Medical Sciences, Iranshahr 9916643535, Iran
2
Student Research Committee, Zahedan University of Medical Sciences, Zahedan 9816743463, Iran
3
Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada
4
Research Institute in Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 3P5, Canada
5
Genetics of Non-communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan 9816743463, Iran
6
Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan 9816743175, Iran
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(8), 425; https://doi.org/10.3390/medicina55080425
Received: 25 June 2019 / Revised: 16 July 2019 / Accepted: 30 July 2019 / Published: 31 July 2019
  |  
PDF [5690 KB, uploaded 8 August 2019]
  |  

Abstract

Background and Objectives: Previous studies have investigated the impact of the ATG16L1 rs2241880 (Thr300Ala) polymorphism on individual susceptibility to cancer, but the conclusions are still controversial. To get a more precise evaluation of the correlation between ATG16L1 rs2241880 polymorphism and cancer susceptibility, we performed a meta-analysis of the association of all eligible studies. Materials and Methods: Searches were performed in the Web of Science, PubMed, Scopus and Google Scholar databases up to November 2018. A total of 12 case-control studies from 9 articles comprising 2254 cases and 4974 controls were included. Statistical analysis was achieved by STATA 14.1 and Review Manager 5.3 software. The odds ratios (ORs) with 95% confidence intervals (95% CIs) under five genetic models were used to determine the strength of association among rs2241880 polymorphism and cancer susceptibility. Results: The findings did not support an association between the rs2241880 variant in either the overall study population or the subgroups, based on cancer types and ethnicity in any of the genetic models. As far as we know, our study is the first meta-analysis of the association between rs2241880 polymorphism and cancer risk. Conclusions: In conclusion, the findings of this meta-analysis proposes that the ATG16L1 rs2241880 polymorphism may not play a role in cancer development. Further well-designed studies are necessary to clarify the precise role of the ATG16L1 rs2241880 polymorphism on cancer risk. View Full-Text
Keywords: ATG16L1; polymorphism; rs2241880; Thr300Ala; cancer; meta-analysis ATG16L1; polymorphism; rs2241880; Thr300Ala; cancer; meta-analysis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Moazeni-Roodi, A.; Tabasi, F.; Ghavami, S.; Hashemi, M. Investigation of ATG16L1 rs2241880 Polymorphism with Cancer Risk: A Meta-Analysis. Medicina 2019, 55, 425.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicina EISSN 1010-660X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top